Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-blinded, Active-controlled, Multinational, Multicenter Study to Assess the Safety and Immunogenicity of a Two-dose Regimen of SKYVaricella® (NBP608) in Children Aged 12 Months to 12 Years

NCT07415252 is registered in ClinicalTrials.gov with SK Bioscience Co., Ltd. as lead sponsor.

NCT NCT07415252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07415252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-blinded, Active-controlled, Multinational, Multicenter Study to Assess the Safety and Immunogenicity of a Two-dose Regimen of SKYVaricella® (NBP608) in Children Aged 12 Months to 12 Years
Lead sponsor
SK Bioscience Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
July 4, 2026
Completion date
January 2, 2028
Enrollment
780 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

varicella (chickenpox)